Grants and Contracts Details
Description
Therapeutic Development Center
Project Summary
Therapeutics Development Centers (TDCs) are CF clinical research centers that have been chosen through a
competitive process to become part of the TDN and receive infrastructure funding from CFF. To become a
TDC, a center must be a CFF-accredited care center with established clinical research programs.
A TDC’s participation in the TDN includes consultative, administrative, and research-support activities. In
addition to conducting clinical studies, TDCs also participate in other TDN initiatives. The functions of a TDC
vary depending on current trial activity and network needs. See expectations of a TDC below.
TDC Selection and Funding Center Selection
All policies regarding the selection of centers to become TDCs are determined by CFF. A competitive renewal
process is conducted every 2 years, and the size of the network may change over time based on an
assessment of CF clinical research needs and available funds. Details regarding the application and review
processes for TDN membership and any current Requests for Application are available on the Centers page of
CFCRNet. Centers selected to be TDCs receive an award notification letter from CFF, including the terms and
conditions of the award.
Infrastructure Funding
Centers approved for funding as TDCs receive infrastructure support from CFF to ensure staff continuity and
efficiency in the conduct of clinical studies. The award is intended to cover personnel, attendance at specific
network meetings, equipment, and supplies. Payment of these award funds is made from CFF to the TDC on a
quarterly basis, contingent upon centers entering key study metrics data into the CF Center Portal. CFF
determines the award size for the upcoming year based on the following factors: 1) the total available funds
within the CFF budget for the upcoming year, 2) the total number of centers to be funded, 3) the number of
patients in the CFF registry at a particular center, and 4) the level of CFF-sanctioned clinical trial activity at that
center.
Funding renewal is on an annual basis contingent upon performance and is granted entirely at CFF’s
discretion. Site performance will be reviewed regularly by the TDN Steering Committee, which may make
recommendations to CFF about continued funding (See Site Performance Review section below). TDCs must
submit an annual progress report including an expenditure report.
Status | Finished |
---|---|
Effective start/end date | 4/1/22 → 3/31/23 |
Funding
- Cystic Fibrosis Foundation: $154,691.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.